Subsequently, C57BL/6 mice were subcutaneously (s.c.)implanted with a B16-OVA tumor and vaccinated with two different Galsome formulations (low and high αGC-dose) or PBS when tumors reached a size of 166±137 mm3 (11 days post inoculation), as shown in Figure 1A. The immune response was evaluated by measuring the number of anti-tumor immune effector cells (iNKT cells and OVA-specific CD8+ T cells) in the spleen 4 days after vaccination, showing a significant increase in iNKT cells and OVA-specific CD8+ T cells upon vaccination of both αGC-doses (Figure 1B-C). This evidence concerns the gene CD8A and neoplasm.